Time filter

Source Type

Lubovich A.,Bnai Zion Medical Center | Hamood H.,Bnai Zion Medical Center | Behar S.,Neufeld Cardiac Research Institute | Rosenschein U.,Bnai Zion Medical Center
Israel Medical Association Journal | Year: 2011

Background: Rapid reperfusion of an infarct-related artery is crucial for the successful treatment of ST elevation myocardial infarction. Every effort should be made to shorten doorto- balloon time. Objectives: To investigate whether bypassing the emergency room (ER) has a positive influence on door-to-balloon time in patients presenting with ST elevation myocardial infarction (STEMI) and whether the reduction in door-to-balloon time improves patients' clinical outcome. Methods: We analyzed data of 776 patients with STEMI from the 2004 and the 2006 Acute Coronary Syndrome Israeli Survey (ACSIS) registry. The ACSIS is a biennial survey on acute myocardial infarction performed in all 25 intensive cardiac care units in Israel during a 2-month period. Twentyfive percent of patients (193 of 776) arrived directly to the intensive cardiac care unit (ICCU) and 75% (583 of 776) were assessed first in the ER. We compared door-to-balloon time, ejection fraction, 30 days MACE (major adverse cardiac and cerebrovascular events) and 30 days mortality in the two study groups. Results: There was significantly shorter door-to-balloon time in the direct ICCU group as compared with the ER group (45 vs. 79 minutes, P < 0.002). Patients in the direct ICCU group were more likely to have door-to-balloon time of less than 90 minutes in accordance with ACC/AHA guidelines (88.7% vs. 59.2%, P < 0.0001). Moreover, patients in the direct ICCU group were less likely to have left ventricular ejection fraction < 30% (5.4% vs. 12.2%, P = 0.045) and less likely to have symptoms of overt congestive heart failure. Lastly, 30 days MACE was significantly lower in the direct ICCU group (22 vs. 30%, P < 0.004). Conclusions: There is significant reduction of the door-toballoon time in the direct ICCU admission strategy. This reduction translates into improvement in clinical outcome of patients. It is reasonable to apply the direct ICCU strategy to patients with STEMI. Source

Kuperstein R.,Leviev Heart Center | Kuperstein R.,Tel Aviv University | Goldenberg I.,Tel Aviv University | Goldenberg I.,University of Rochester | And 8 more authors.
Circulation: Heart Failure | Year: 2014

Background - Left atrial volume (LAV) is an important marker of heart failure (HF) severity. We hypothesized that LAV independently correlates with clinical outcomes in patients who receive cardiac resynchronization therapy with a defibrillator (CRT-D) and can be used for improved risk assessment in this population. Methods and Results - The benefit of CRT-D versus defibrillator-only therapy in reducing the risk of HF or death was assessed by LAV (dichotomized at the upper quartile >52 mL/m2) among 1785 patients enrolled in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT) study. Landmark analysis was used to evaluate the relationship between LAV response to CRT-D and subsequent clinical outcomes. Multivariable analysis showed that patients with a higher baseline LAV experienced 69% (P<0.001) and 59% (P=0.02) increased hazard for HF or death and for all-cause mortality, respectively, independently of baseline left ventricular volume. CRT-D was associated with a significant reduction in LAV compared with defibrillator-only therapy (-28% versus -10%, respectively; P<0.001). Landmark analysis showed that after CRT-D implantation each 1% reduction in LAV was independently associated with a corresponding 4% reduction in the hazard of subsequent HF or death (P<0.001). The assessment of LAV change after CRT implantation improved prediction of clinical response to the device compared with assessment of the corresponding changes in left ventricular volume. Conclusions - LAV is an independent correlate of clinical outcomes in mildly symptomatic HF patients treated with CRT-D. CRT exerts pronounced reverse remodeling effects on the left atrium that independently correlate with improved clinical outcomes after device implantation. © 2013 American Heart Association, Inc. Source

Kopel E.,Neufeld Cardiac Research Institute | Klempfner R.,Neufeld Cardiac Research Institute | Goldenberg I.,Neufeld Cardiac Research Institute | Goldenberg I.,Tel Aviv University
European Journal of Heart Failure | Year: 2014

Aims: Influenza vaccine is a well-recommended secondary prevention measure for improving survival in patients with coronary artery disease, but it has generally been less studied in heart failure. We ask whether having influenza vaccination is associated with survival among patients with acute heart failure (HF). Methods and results: This was a prospective population-based cohort study accompanied by an analysis of two cross-sectional population samples for external validation of baseline characteristics differences. We analysed all 1964 ambulatory patients with acute HF aged ≥50 years who were admitted to the Heart Failure Survey in Israel (HFSIS). We used the Israel Health Survey (IHS) 2009 and the Behavioural Risk Factor Surveillance System (BRFSS) 2003-2004 surveys (274 535 participants) for external validation. In the HFSIS, the multivariate-adjusted hazard ratios for in-hospital, 1 and 4 year mortality outcomes of influenza-vaccinated patients were 0.71 (P = 0.19), 0.81 (P = 0.04), and 0.83 (P = 0.006), respectively. In the IHS validation sample, a recent physician visit [odds ratio (OR) 1.61; 95% confidence interval (CI) 1.43-1.80] or having supplementary health insurance (OR 1.39; 95% CI 1.19-1.61) were associated with higher likelihood of being vaccinated against influenza. In the BRFSS validation sample, having > 1 healthcare providers (OR 2.31; 95% CI 2.22-2.40) or having any healthcare coverage were associated with higher likelihood of being vaccinated (OR 1.59; 95% CI 1.54-1.65). Conclusions: Influenza vaccine might improve survival among patients with acute HF. This association, however, could be affected by unmeasured confounding and bias due to baseline medical surveillance and socioeconomic differences between vaccinated and non-vaccinated patients. © 2013 European Society of Cardiology. Source

Korn-Lubetzki I.,Shaare Zedek Medical Center | Molshatzki N.,Stroke Center | Benderly M.,Neufeld Cardiac Research Institute | Steiner I.,Rabin Medical Center
European Neurology | Year: 2013

Background: Our clinical experience suggests that the outcome of cerebellum-brainstem ischemic strokes is better than that of hemispheric ischemic strokes. Methods: Within the setting of 2 national Israeli prospective stroke surveys, we analyzed risk factors, etiology, severity at presentation, and prognosis of first ischemic cerebellum-brainstem stroke (259 patients), comparing with strokes within the anterior circulation (1,029 patients). Results: Patients with cerebellum-brainstem strokes were younger and had less frequently atrial fibrillation and congestive heart failure. Cardioembolic etiology was significantly less prevalent (p < 0.001). Severity at presentation was milder (p < 0.001). At discharge, worsening of the modified Rankin Scale was present in a smaller number of patients (p < 0.001); more returned to their home (p < 0.001). Six-month and 1-year mortality were lower (p < 0.001 for both). Adjusted logistic regression models showed that patients with cerebellum-brainstem strokes had 50% smaller chances of dying (OR 0.55; 95% CI 0.31-0.98) and a smaller chance of worsening of the modified Rankin Scale at discharge (OR 0.61; 95% CI 0.46-0.82). Conclusions: Cerebellum-brainstem strokes are less frequently cardioembolic, have a less severe presentation, and carry a better immediate and long-term prognosis. © 2012 S. Karger AG, Basel. Source

Beinart R.,Heart Institute | Abu Sham'a R.,Heart Institute | Segev A.,Heart Institute | Hod H.,Heart Institute | And 5 more authors.
American Heart Journal | Year: 2010

Background: Acute coronary syndrome (ACS) is associated with activation of platelets and the coagulation system which could influence the incidence of early stent thrombosis (EST). We aimed to determine the incidence and predictors of EST in patients undergoing coronary stenting during ACS. Methods: The study comprised 1202 consecutive patients, drawn from a nationwide ACS survey, who underwent coronary stenting during ACS and were followed up for 30 days. Early stent thrombosis was based on the Academic Research Consortium definition. Results: Thirty patients (2.5%) sustained EST. The occurrence of EST in patients with unstable angina/non-ST-elevation myocardial infarction and ST-elevation myocardial infarction (STEMI) was 0.9% and 3.9%, respectively (P < .05), and was even higher (5.2%) in STEMI patients who underwent primary percutaneous coronary intervention. On multivariate analysis, STEMI (OR 6.3, 95% CI 2.1-18, P = .0008), multivessel disease (OR 5.9, 95% CI 1.9-21, P = .003) and Killip class ≥2 (OR 2.9, 95% CI 1.3-6.6, P = .008) were independent correlates of EST. The use of bare versus drug-eluting stents was not associated with any significant difference in EST. Conclusions: Patients presenting with STEMI who are hemodynamically unstable and have multivessel coronary disease undergoing coronary stenting during ACS, are at increased risk of EST. © 2010 Mosby, Inc. All rights reserved. Source

Discover hidden collaborations